All articles by Srivani Venna

  1. WHO says investment in new R&D tools can eradicate malaria

    The World Health Organization (WHO) has claimed that malaria can be eradicated with accelerated research and development (R&D), using new…
    Read More…

    23 Aug
  2. China approves Gilead’s HIV-1 drug candidate Biktarvy

    The China National Medical Products Administration (NMPA) has approved Gilead Sciences’ Biktarvy, a once-daily single-tablet regimen (STR) to treat HIV-1…
    Read More…

    12 Aug
  3. Oric closes funding to develop glucocorticoid antagonist ORIC-101

    Oric Pharmaceuticals has closed a Series D financing to support the continued development of a clinical-stage, selective and potent glucocorticoid…
    Read More…

    9 Aug
  4. Dynacure secures orphan drug designation from FDA for DYN101

    Dynacure has secured orphan drug designation from the US Food and Drug Administration (FDA) for investigational antisense medicine DYN101, which…
    Read More…

    9 Aug
  5. UF researchers focus on new drug candidate Apratoxin S4 to treat vision loss

    Researchers from the University of Florida (UF) College of Pharmacy have announced a partnership to focus on a new drug…
    Read More…

    9 Aug
  6. Takeda submits NDA for SC formation of ulcerative colitis treatment

    Takeda Pharmaceutical has submitted a new drug application (NDA) in Japan for a subcutaneous (SC) formulation of vedolizumab to treat…
    Read More…

    8 Aug
  7. Bayer agrees to acquire biotech BlueRock for $1bn

    German multinational pharmaceutical company Bayer has signed an agreement to acquire US-based biotechnology company BlueRock Therapeutics. Bayer and founding investor…
    Read More…

    8 Aug
  8. Hummingbird and Cancer Research UK to develop antibody drug HMBD-001

    Biotechnology company Hummingbird Bioscience and Cancer Research UK have collaborated to develop the former’s anti-HER3 clinical grade antibody drug, HMBD-001…
    Read More…

    8 Aug
  9. GSK transfers rights to Ebola vaccines development to US institute

    Drug manufacturer GlaxoSmithKline (GSK) transfers its rights to advance the development of the deadly Ebola Zaire, Ebola Sudan and Marburg…
    Read More…

    7 Aug
  10. Permira affiliate to buy small molecule company Cambrex for $2.4bn

    An affiliate of private equity firm Permira Funds is set to acquire small molecule company Cambrex in a deal valued…
    Read More…

    7 Aug
Close
Close
Close

Go Top